Home
Scholarly Works
KeyVibe-003: Randomized, double-blind, phase 3...
Conference

KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC

Authors

Cho BC; Juergens RA; Cheng Y; de Castro G; Erman M; Bauman JR; Takahashi T; Schwarzenberger P; Li C; Pietanza MC

Volume

82

Publisher

AMER ASSOC CANCER RESEARCH

Publication Date

June 15, 2022

Name of conference

Annual Meeting of the American-Association-for-Cancer-Research (AACR)

Conference place

LA, New Orleans

Conference start date

April 8, 2022

Conference end date

April 13, 2022

Conference proceedings

CANCER RESEARCH

Issue

12

ISSN

0008-5472

Contact the Experts team